Skip to main content

For informational and research purposes only.

Medical DisclaimerTerms of Use

Testosterone Cypionate vs Enanthate: The Definitive Guide

The only head-to-head study, why half-life figures disagree, what is really in each vial, switching and mixing, cost and where each is sold.

Testosterone cypionate vs enanthate at a glance.

Testosterone cypionate vs enanthate at a glance. The same testosterone with two different ester tails, both dissolved in oil and injected into a muscle; Xyosted, an enanthate autoinjector, goes under the skin. The drawing shows the identical four-ring testosterone skeleton twice. On top it carries the cypionate tail, 8 carbons with 5 of them in a ring; underneath, the enanthate tail, a straight chain of 7 carbons. By weight, cypionate is about 70% testosterone and enanthate about 72%. A generic vial of oil sits beside them. Simplified drawings, not 3D structures or product images. How it works: the ester sits in an oil pool in the muscle and releases slowly over days; the body removes the tail, so ordinary testosterone enters the blood; in the only direct comparison, 6 healthy men given equal testosterone as either ester in 1980 had identical levels. A schematic shows that shared curve: from a starting level of about 500 ng/dL up to about 1,350 ng/dL at 24 hours, about three times the start, and back to the starting level by day 10. What to track: testosterone at the same point in the dosing interval, and hematocrit. What it is: two esters of testosterone in oil, injected every 1 to 4 weeks. Key number: the same US label range for both, 50 to 400 mg every 2 to 4 weeks; the Endocrine Society guideline names the two together, 75 to 100 mg weekly or 150 to 200 mg every 2 weeks. What differs: the oil, the strength (US cypionate 100 or 200 mg/mL; enanthate 200 mg/mL in the US and Canada and 250 mg/mL in the UK, Australia and much of Europe), where each is sold and the price (US pharmacies pay about $1.79 per 100 mg of generic cypionate and about $7.24 per 100 mg of generic enanthate). Status, the same for both: US Schedule III, UK Class C, Canada Schedule IV, prescription-only in Australia (Schedule 4), prohibited in sport at all times under the WADA list. Checked September 2026.

Cypionate vs enanthate

The same testosterone with two different ester tails

Cypionate: Depo-Testosterone, Azmiro, generics (US) · Taro (Canada) · Testex Prolongatum (Spain)
Enanthate: generic vials, Xyosted (US) · Testosterone Enantate (UK) · Primoteston Depot (Australia) · Androtardyl (France)

Two testosterone esters In oil Intramuscular injection (Xyosted: subcutaneous) C27H40O3 vs C26H40O3

O O O O O O Cypionate tail about 70% testosterone Enanthate tail about 72% testosterone Same testosterone identical in both In oil either ester O O O O O O Cypionate tail about 70% testosterone Enanthate tail about 72% testosterone Same testosterone identical in both
  • Testosteroneidentical in both
  • Cypionate tail8 carbons, 5 in a ring
  • Enanthate tailstraight 7-carbon chain
  • Oilvaries by product and country

Simplified drawings; the tail changes release chemistry and weight, not the hormone released. The vial is generic, not a product image.

How it works

Human study (one crossover, 6 healthy men)

02468101214about 1,350 ng/dL at 24 hours (about 3× the start)back to about 500 by day 10

Days after one injection, equal testosterone as either ester. The two dots are the values reported from the study; the line between them is a smooth sketch.

What to track after a switch: testosterone at the same point in the dosing interval, and hematocrit.

  1. Oil depot

    The ester sits in an oil pool in the muscle and releases slowly over days.

  2. Tail clipped

    The body removes the tail; ordinary testosterone enters the blood.

  3. Same curve

    Equal testosterone as either ester gave identical levels (6 healthy men, 1980).

What it is

Two esters of one hormone

Testosterone in oil, injected every 1–4 weeks

Key number

50–400 mgevery 2–4 weeks on both US labels

Endocrine Society names both: 75–100 mg weekly or 150–200 mg every 2 weeks

What differs

Oil, strength, country, price

Cypionate 100 or 200 mg/mL; enanthate 200 or 250 mg/mL. US pharmacies pay about $1.79 vs $7.24 per 100 mg

Status

The same for both

  • Controlled: US Schedule III, UK Class C, Canada Schedule IV
  • Prescription-only in Australia
  • Sport: prohibited at all times (WADA S1)

Checked Sep 2026

Conceptual summary. The molecules and vial are simplified drawings, not product images. The shared release curve is drawn from the only direct comparison in people (one injection each, 6 healthy men); doses, oils, status and sport rules come from current labels, guidelines and regulators (checked September 2026).
Published by DoserlyUpdated Next scheduled review: December 202623 min readHow this guide was made
In this guide

What is the difference between testosterone cypionate and enanthate?

Very little, where it counts. Both are prescription testosterone joined to a small chemical tail and dissolved in oil, injected into a muscle every week or every few weeks; the body clips the tail off and releases ordinary testosterone. The real differences are in the vial: the oil, the preservative, the strength, where each is sold and what it costs. [1], [7], [8]

The names describe the tails. Cypionate (cyclopentylpropionate) is an 8-carbon tail with 5 of its carbons in a ring; enanthate (heptanoate) is a straight 7-carbon chain. The tails change the weight of the molecule, not the hormone it releases: 100 mg of cypionate carries about 70 mg of testosterone and 100 mg of enanthate about 72 mg, a difference of about 3%. [1], [7], [2], [9]

Testosterone itself lasts only 10 to 100 minutes in the blood. The multi-day figures quoted for both esters describe how slowly the oil depot in the muscle releases it. [1]

This guide is about prescribed testosterone replacement therapy for men, not non-prescribed "cycles" (TRT vs steroids).

Testosterone cypionate vs enanthate at a glance

Status and prices were checked in September 2026. Doses are label and guideline figures for context, not a plan.

CypionateEnanthate
Brand namesDepo-Testosterone, Azmiro, generics (US); Taro (Canada); Testex Prolongatum (Spain)Generic vials (US, Canada); Xyosted (US); Testosterone Enantate (UK); Primoteston Depot (Australia); Androtardyl (France)
Share that is testosteroneAbout 70%About 72%
Half-life you will see quotedAbout 8 days (US label)2 to 8 days, depending on the source; none on US labels
US label dose50–400 mg every 2–4 weeks50–400 mg every 2–4 weeks (vials)
Guideline example (Endocrine Society 2018)75–100 mg weekly or 150–200 mg every 2 weeksSame: the guideline names the two together
Labeled routeIntramuscularIntramuscular. Xyosted starts at 75 mg weekly and is subcutaneous (into the fatty layer under the skin)
StrengthUS: 100 or 200 mg/mL. Canada: 100 mg/mLUS and Canada: 200 mg/mL. UK, Australia and much of Europe: 250 mg/mL
Oil and preservativeUS and Canada: cottonseed oil, benzyl benzoate, benzyl alcoholUS and Canadian vials: sesame oil, chlorobutanol. Xyosted: sesame oil, no preservative. UK, Australia, France, Germany: castor oil, benzyl benzoate, no preservative
Container10 mL multi-dose vial or 1 mL vial; Azmiro prefilled syringe5 mL multi-dose vial (US, Canada); 1 mL ampoules (UK, Europe); Xyosted autoinjector
Where it is soldUS, Canada, Spain; no UK or Australian licenceUS, Canada, UK, Australia, France and other European countries; not authorised in Spain
What US pharmacies payAbout $1.79 per 100 mg (10 mL vial)About $7.24 per 100 mg (5 mL vial)
Can a pharmacist swap one for the other?No: FDA treats them as different active ingredientsNo
Red blood cells, fertility, heart risk, legal and sport statusSame for bothSame for both

[1], [17], [3], [18], [7], [2], [9], [19], [6], [5], [4], [20], [8], [21], [22], [23], [24], [10], [11]

Where these numbers come from

Chemistry, doses, oils and containers come from the current US labels (Depo-Testosterone, DailyMed version effective August 21, 2026; generic cypionate from Hikma and Padagis; Azmiro, July 2025; generic enanthate from Hikma, May 2026, and Eugia, June 2026; Xyosted, July 2025), the Canadian monographs (Taro cypionate, May 2022; Hikma enanthate, March 2023), and the UK, Australian, French, German and Spanish product information. The share that is testosterone is worked out from the label molecular weights (cypionate 412.61, enanthate 400.59) and testosterone's weight of 288.42; the UK label's own figure (250 mg enanthate is about 180 mg testosterone) agrees. [1], [21], [25], [17], [7], [26], [2], [3], [4], [9], [19], [6], [20], [18]

The guideline row is the Endocrine Society's 2018 schedule, which the UK Society for Endocrinology repeats for either ester. Prices are the National Average Drug Acquisition Cost (NADAC) for 200 mg/mL generic vials in the week of September 23, 2026; per-100 mg figures are simple arithmetic from the per-mL price. [8], [27], [10]

Not used: carbon counts and equivalence codes from a widely quoted 2016 review, which reverses the two esters' carbon counts, and a 2,261 ng/dL enanthate peak that older pages presented as a comparison with cypionate (it came from an enanthate-only group in a different study).

Open the searchable source directory

What is the real difference?

On blood levels, dose and risks, the evidence shows no meaningful difference. The differences that matter in practice are product details: oil, strength, container, country and cost.

Do they give different blood levels?

No difference was found in the only study that compared them directly. In a 1980 randomized crossover study, 6 healthy men aged 20 to 29 each received one injection of 200 mg of cypionate and, separately, 194 mg of enanthate, amounts that carry the same 140 mg of testosterone. Blood levels were identical: about three times the starting level within 1–2 days (about 1,350 ng/dL, or 46.8 nmol/L, at 24 hours) and back to the starting level (about 500 ng/dL, or 17.3 nmol/L) by day 10. [3], [4], [5]

That study is small and old: one injection each, in young men with normal testosterone, with 1980 blood tests. In men with hypogonadism, each ester has only been studied on its own, with different men, doses and lab methods, so those studies cannot be compared side by side. In 11 such men, testosterone peaked between days 2 and 5 after 200 mg of cypionate and was back to baseline by days 13–14; in 23 men on enanthate, 200 mg every 2 weeks and 300 mg every 3 weeks appeared to work best. [28], [29]

Which one lasts longer?

Neither, as far as the evidence goes. Cypionate's reputation for lasting longer comes from comparing numbers that were never measured the same way. [1], [7]

SourceCypionateEnanthateWhat it describes
US labelsAbout 8 daysNot statedAfter intramuscular injection
European Association of Urology (EAU) guideline 20268 days4–5 daysFigures in its product table
UK and Polish product information2–3 daysTestosterone in the blood after injection
Swedish product informationAbout 4.2 daysAfter 200 mg in men with hypogonadism
French product informationAbout 4.5 daysRelease of the ester from the injection site
2015 autoinjector studyAbout 7.2 days200 mg intramuscular every 2 weeks, 10 men
German product information8 daysAfter injection
2018 modelMedian 4.05 daysModel of 31 healthy men given 100 to 500 mg weekly in a study of abuse effects

[1], [7], [30], [9], [31], [32], [6], [33], [20], [34]

Cypionate figures vary too, from about 8 days on the US label to 4.05 days in a 2018 model. [1], [34] Both are short-acting esters that guidelines dose on the same schedules. [30], [8]

Chart of the half-life figures quoted for each ester, in days, by source. Cypionate: US label about 8 days after injection into a muscle; EAU guideline 2026 table 8 days; a 2018 model of 31 healthy men given 100 to 500 mg weekly in a study of abuse effects, median 4.05 days. Enanthate: UK and Polish product information 2 to 3 days for testosterone in the blood; Swedish product information 4.2 days (apparent, 200 mg in men with hypogonadism); EAU guideline 2026 table 4 to 5 days; French product information about 4.5 days for release from the injection site; a 2015 study about 7.2 days (apparent, 200 mg every 2 weeks, 10 men); German product information 8 days after injection; US enanthate labels give none. The figures overlap and measure different things. The only direct comparison, 6 healthy men in 1980, found identical blood levels at equal testosterone content.

Half-life figures for each ester, by source

Each figure measures something different, so they cannot be lined up as a contest.

Cypionate

US label (Depo-Testosterone)
About 8 days. After injection into a muscle.
EAU guideline 2026
8 days. Figure in its product table.
2018 model (Bi et al.)
Median 4.05 days (model). Model: 31 men, 100–500 mg weekly, abuse study.

Enanthate

UK product information
2–3 days. Testosterone in the blood.
Polish product information
2–3 days. Testosterone in the blood.
Swedish product information
About 4.2 days. Apparent: 200 mg, men with hypogonadism.
EAU guideline 2026
4–5 days. Figure in its product table.
French product information
About 4.5 days. Release from the injection site.
2015 study (Kaminetsky et al.)
About 7.2 days. Apparent: 200 mg every 2 weeks, 10 men.
German product information
8 days. After injection.
US labels
Not stated. No half-life given.

Only direct comparison (6 healthy men, 1980): identical blood levels at equal testosterone content.

The half-life figures quoted for each ester, by source. The ranges overlap because the figures measure different things (blood half-life, release from the injection site, or a model estimate) in different people and doses. The only study that compared the two esters directly found identical blood levels. Figures come from product labels, a guideline table and human studies; this is not a prediction for any person. Sources: Depo-Testosterone US label · EAU guideline 2026 · Bi et al. 2018 cypionate model · Testosterone Enantate UK product information · Polish product information (Jelfa) · Swedish product information (SIT) · French product information (Androtardyl) · Kaminetsky et al. 2015 autoinjector study · German product information (Panpharma).

What is actually in each vial?

The oil follows the product and the country, not the ester. US and Canadian cypionate comes in cottonseed oil with benzyl benzoate (which helps the hormone dissolve) and benzyl alcohol as a preservative. US and Canadian enanthate vials use sesame oil with chlorobutanol. In the UK, Australia, France, Germany and Sweden, enanthate comes in castor oil with benzyl benzoate; Poland's uses peanut oil, and Spain's cypionate uses olive oil. [1], [21], [3], [7], [26], [9], [19], [6], [20], [32], [31], [18]

  • Allergies. Labels rule out use with an allergy to the product; Xyosted names sesame oil, and the Polish label names peanut and soy. Among US products, only Xyosted has no preservative. The single-use ampoules and syringes sold in the UK, Australia, France, Germany and Sweden list none either, though they do contain benzyl benzoate. No study shows that products without a preservative are better tolerated. [1], [7], [2], [31], [9], [19]
  • Reactions and pain. Proven reactions to one ingredient are single case reports (benzyl benzoate, castor oil), both with undecanoate injections. No study compares pain or lumps between the esters or the oils; of 551 weekly castor-oil enanthate injections in 26 men, 70.6% caused no complaint and 29.4% minor pain or bleeding. [35], [36], [37]
  • Crystals. Both US labels say crystals can form in the cold and redissolve with warming; no source compares the two. [1], [7]

Two branded products stand apart: Azmiro, cypionate 200 mg/mL in a single-dose vial or a prefilled syringe given by a health professional, and Xyosted, enanthate in a weekly autoinjector for the abdomen. One line of label wording also differs: the US enanthate label says injections more often than every 2 weeks are rarely indicated, and the cypionate label does not, although guidelines now give weekly schedules for both. [17], [2], [7], [1], [8]

Can a pharmacy swap one for the other?

No. FDA treats different esters of the same hormone as different active ingredients ("pharmaceutical alternatives"), not rated as equivalent. Even for one ester, FDA rates oil injections as interchangeable only when the ester, the strength and the oil are all identical, and the Azmiro label says injectable testosterone products are not substitutable milligram for milligram. [11], [17]

This is a pharmacy rule, not evidence that they work differently: a switch needs a new prescription.

Which is cheaper?

Checked September 2026. In the United States, cypionate is usually cheaper, but the container matters as much as the ester. Pharmacies paid on average $3.58 per mL for 10 mL vials of generic cypionate 200 mg/mL, $11.39 per mL for 1 mL cypionate vials and $14.48 per mL for 5 mL vials of generic enanthate. What you pay depends on the pharmacy and insurance. Cypionate is also far more used: Medicare Part D paid for 1,118,253 generic cypionate prescriptions in 2024 (an average of $37.01 each before rebates) against 10,421 for generic enanthate (about $76 each). [10], [38], [39]

Where is each one sold?

Checked September 2026. A licence shows that a product is authorised, not that it is in stock.

CountryCypionateEnanthate
United StatesDepo-Testosterone, Azmiro, genericsGeneric vials, Xyosted
CanadaTaro (Depo-Testosterone cancelled July 18, 2025)Hikma (Delatestryl cancelled December 18, 2025)
United KingdomNo licence; imported as an unlicensed medicineTestosterone Enantate 250 mg/mL
AustraliaNo productPrimoteston Depot
SpainTestex ProlongatumNo authorised product

[40], [41], [42], [22], [43], [23], [18], [24]

France markets enanthate as Androtardyl and a generic (about €6 an ampoule, 65% reimbursed), and enanthate product information also exists in Germany, Sweden and Poland, where current marketing was not confirmed. In the UK, six licence holders have notified the regulator since 2021 that they intend to import cypionate as an unlicensed medicine. See TRT in the UK and TRT in Europe. [6], [44], [20], [32], [31], [43]

Which suits which situation, according to guidelines?

No guideline prefers one ester over the other. They are named together, with the same doses and the same blood-test timing. This section describes what guidelines and labels say; it is not a personal plan.

GuidelineWhat it says about cypionate and enanthate
Endocrine Society (2018)"Enanthate or cypionate": 75–100 mg weekly or 150–200 mg every 2 weeks
American Urological Association (AUA) (2018, reconfirmed 2024)Groups them as short-acting injections; prefers 100 mg weekly
Society for Endocrinology (UK) (2022)"Enanthate or cypionate": 150–200 mg every 2 weeks, or 50–100 mg intramuscular or subcutaneous weekly
EAU (2026)Both are short-term esters given every 2–4 weeks
US Veterans Affairs (VA) (2026)Cypionate or enanthate, 50–100 mg weekly or 100–200 mg every 2 weeks
Canadian Urological Association (2021)Enanthate 100–200 mg every 1–4 weeks; cypionate 200 mg every 2 weeks or 100 mg weekly
British Society for Sexual Medicine (2023)Enanthate every 2–3 weeks; cypionate every 1–4 weeks, with little long-term data

[8], [45], [27], [30], [46], [47], [48]

In practice, the choice follows the situation rather than the ester:

  • Where you live decides what is licensed: only enanthate in the UK and Australia, only cypionate in Spain. [22], [23], [24]
  • An allergy to an oil or preservative points to a different product, which may or may not be a different ester. [7], [2]
  • A weekly self-injected device exists only for enanthate (Xyosted). [2]
  • Cost favors generic cypionate in most US pharmacies. [10]
  • Trying to conceive rules out both (TRT and fertility). [49]

Can both be injected subcutaneously?

In studies, yes, although US vial labels say muscle only. In 63 transgender men on weekly subcutaneous cypionate or enanthate (pooled), all reached the normal male range, and all 22 who had used muscle injections before preferred the new route. In 234 men with hypogonadism, hematocrit and estradiol were lower on a weekly subcutaneous enanthate autoinjector than on weekly intramuscular cypionate, but the ester, route and device all differed, so it cannot show that either ester is better. See how to inject testosterone. [1], [50], [51]

When do guidelines check testosterone on either ester?

The same way for both, although guidelines disagree with each other. The Endocrine Society measures midway between injections and adjusts above 600 or below 350 ng/dL (about 21 or 12 nmol/L); the AUA checks no earlier than after 3–4 injections; the UK Society for Endocrinology uses the trough level, just before the next dose; and the Xyosted label uses a trough 7 days after a dose, after 6 weeks. See TRT blood work. [8], [45], [27], [2]

Switching between cypionate and enanthate

Switches usually happen for practical reasons: a shortage, an insurance change, a move abroad or a pharmacy supplying a different product.

Do you need to change the dose when switching?

No label gives a rule for switching between the two esters. The evidence that the same milligram dose works is indirect but consistent: the same label ranges, the same guideline schedules and identical levels in the one direct comparison. The 3% difference in testosterone per milligram is small. The prescriber decides, and a blood test afterward shows how it went. [1], [7], [8], [3]

How many mL or units after a switch?

The milligram dose can stay the same while the volume changes, because the strength of the vial can change. This is where switching goes wrong. On a U-100 insulin syringe, 100 units equal 1 mL:

100 mg doseVolumeSyringe units (U-100)
At 100 mg/mL (Canadian cypionate)1.0 mL100 units
At 200 mg/mL (most US vials of either ester)0.5 mL50 units
At 250 mg/mL (enanthate in the UK, Australia and much of Europe)0.4 mL40 units

[3], [1], [7], [9]

Keeping the old volume changes the dose: 0.5 mL from a 250 mg/mL ampoule is 125 mg, 25% more than 100 mg, and 0.4 mL from a 200 mg/mL vial is 80 mg. Check the mg/mL on the new label every time; Doserly's TRT dose calculator converts any dose and strength into mL and units. These are labeled and guideline doses for adult men; testosterone for women uses different products and far smaller doses (testosterone therapy for women).

Three schematic 1 mL U-100 syringes marked 0 to 100 units, drawn like the Doserly calculators, each holding the same 100 mg. At 100 mg/mL (Canadian cypionate) it is 1 mL, the whole syringe, 100 units. At 200 mg/mL (most US vials of either ester) it is 0.5 mL, 50 units. At 250 mg/mL (UK, Australian and European enanthate) it is 0.4 mL, 40 units. A side note shows that keeping the same volume after a switch changes the dose: 0.5 mL at 250 mg/mL is 125 mg, 25% more, and 0.4 mL at 200 mg/mL is 80 mg. Arithmetic only; not a dosing instruction.

The same 100 mg is a different volume at each strength

mL = mg ÷ mg/mL. On a U-100 syringe, 100 units = 1 mL, so units measure volume, not testosterone.

100 mg/mL (Canadian cypionate)
100 mg ÷ 100 mg/mL = 1 mL = 100 units
200 mg/mL (most US vials of either ester)
100 mg ÷ 200 mg/mL = 0.5 mL = 50 units
250 mg/mL (UK, Australian, European enanthate)
100 mg ÷ 250 mg/mL = 0.4 mL = 40 units

Same volume, new strength

0.5 mL at 250 mg/mL = 125 mg (25% more than 100 mg).

0.4 mL at 200 mg/mL = 80 mg.

Arithmetic only; not a dosing instruction. Check the mg/mL on your label; the TRT dose calculator converts any dose and strength into mL and units.

The same 100 mg dose drawn from vials of three strengths, shown on a 1 mL U-100 syringe. The dose does not change; the volume does. Arithmetic from the strengths on current product labels; not a dosing instruction. Sources: Depo-Testosterone US label · Testosterone enanthate US label (Hikma) · Testosterone Enantate UK product information · Taro cypionate monograph (Canada).

When should blood be checked after a switch?

At the same point in the injection interval as before, so old and new results can be compared. No guideline gives a separate rule for a switch; the usual timing rules above apply (when guidelines check). [45], [2]

Can cypionate and enanthate be mixed?

No study or guideline has tested mixing the two esters in one syringe or vial. US labels do not mention it, and the UK, Swedish and French enanthate product information say the product must not be mixed with other medicines because no compatibility studies have been done. When one man asked about storing leftover enanthate from an ampoule in an emptied cypionate vial, replies raised the risk of contamination. To use up one product before starting another, ask the pharmacist or prescriber how to change over. [1], [7], [9], [32], [6], [52]

What if there is a shortage?

Checked September 2026. FDA's shortage database lists no testosterone shortage. Men in the UK and the US describe local enanthate supply problems in the past year. A UK pharmacy that could not supply enanthate quoted cypionate at more than double the price, and a US man who said cypionate gave him flu-like symptoms was told pharmacies near him could not get enanthate, while replies from other areas said they could still fill it. No regulator record confirming those shortages was found. [53], [54], [55]

What are the shared risks?

Both esters are the same hormone given the same way, so they share the same risks and rules. The details are in each medicine's guide (cypionate, enanthate).

Is one safer than the other?

No study shows that either ester is safer. For men with a confirmed diagnosis and regular monitoring, both have a long record as standard treatment, with the same labeled warnings: a rise in red blood cells, blood clots, higher blood pressure, fluid retention, breast enlargement, prostate effects and loss of fertility. Side-effect studies used one ester or pooled the two, as one clinic study did with men on "cypionate or enanthate" weekly. [1], [7], [56]

  • Red blood cells. In a network meta-analysis (a study that combines many trials to compare treatments indirectly) of 29 randomized trials, cypionate and enanthate injections, analyzed together, raised hematocrit by about 4.0 percentage points more than placebo (gel 3.0). The difference between injections and gel was not statistically significant. See hematocrit on TRT. [57]
  • Fertility. Both switch off sperm production: weekly 200 mg of enanthate left 157 of 271 healthy men with no sperm (azoospermia) in three consecutive samples, a cumulative rate of 65% by 6 months, in a World Health Organization trial, and cypionate 100 mg weekly impaired it too. See TRT and fertility. [58], [59]
  • Estradiol. Some testosterone is converted into estradiol, which rises with it. No study compares the esters, and no guideline sets a routine estradiol target. See estrogen on TRT. [28], [45]
  • Oil cough. Rarely, oil reaches the lungs as tiny droplets right after an injection (pulmonary oil microembolism), causing a sudden cough. By 2013, FDA had found 33 reports of severe oil reactions or severe allergic reactions (anaphylaxis) over 44 years, across all approved testosterone injections combined. [60]

The heart. The largest safety trial, TRAVERSE, tested a daily gel, not injections, in 5,204 men aged 45 to 80 with low testosterone and heart disease or high heart risk. Heart attack, stroke or heart death occurred in 182 of 2,596 men on testosterone (7.0%) and 190 of 2,602 on placebo (7.3%), a hazard ratio of 0.96 (about the same risk), which ruled out a large rise in risk. Atrial fibrillation (an irregular heartbeat) occurred in 3.5% vs 2.4%, acute kidney injury (a sudden drop in kidney function) in 2.3% vs 1.5% and pulmonary embolism (a blood clot in the lungs) in 0.9% vs 0.5%, all more common on testosterone. Fractures occurred in 91 of 2,601 men on testosterone (3.5%) and 64 of 2,603 on placebo (2.5%). Men used the gel for 21.7 months on average, and about 61% stopped early. [61], [17], [62]

Whether those results apply to injections, with their higher peaks, is not known. The US vial labels of both esters still say long-term heart-safety trials "have not been conducted", while the Azmiro and Xyosted labels carry the TRAVERSE results; neither ester has a boxed warning. See TRT and heart health. [1], [7], [17], [2], [63]

Who should be especially cautious?

The same people, whichever ester:

  • Men who want children now or soon: guidelines advise against testosterone. [49]
  • Men with prostate or breast cancer, a high hematocrit, heart, kidney or liver disease, uncontrolled high blood pressure or untreated severe sleep apnea. [1], [8]
  • Anyone allergic to an ingredient, such as sesame, cottonseed, castor or peanut oil or a preservative: check the product's own label. [7], [2], [31]
  • Women and teenagers: testosterone can harm an unborn baby, and use in teenagers is specialist care only. [1]
  • Drug-tested athletes: both are banned at all times. [16]

Do they interact with other medicines differently?

No. The labels list the same interactions: testosterone can change the effect of blood thinners (oral anticoagulants), lower blood sugar and insulin needs, and add to fluid retention with corticosteroids. Bring a full list of everything you take to a pharmacist or doctor. [1], [17]

Checked September 2026. Rules differ by country and change often.

  • United States. Testosterone and its esters are Schedule III controlled substances; both are FDA-approved. Label changes FDA requested in June 2026, such as removing the "age-related" limitation, are not yet in the labels. [12], [64]
  • Canada. Testosterone is a Schedule IV controlled substance. [13]
  • United Kingdom. Testosterone is a Class C controlled drug. [14]
  • Australia. Testosterone is a Schedule 4 (prescription-only) medicine with extra controls on possession. [15]
  • European Union. Rules are national (which products are licensed where). [18], [24]
  • Sport. Testosterone and its esters are on the World Anti-Doping Agency (WADA) list, banned in and out of competition, and the 2027 list keeps that. [16], [65]

A "research use only" label on a vial does not make it legal, tested or the same as a licensed product.

What do people report after switching?

Public forums are full of switch stories, and they point both ways. The accounts below come from public Reddit threads from the past year and are described without identifying anyone.

Do most people notice a difference?

Many say no. One man reported no difference over 12 weeks on enanthate after years on cypionate; another, using the same weekly dose of each, reported no change and steady blood results. When a clinic ran out of enanthate, several replies described no noticeable change, while others described changes in libido, pain or reactions. [66], [67], [68]

What about people who felt a difference?

A minority describe one, and in almost every account something else changed at the same time:

  • Better on enanthate. One man moved from several cypionate schedules to 75 mg of enanthate weekly and described steadier weeks, better libido and blood pressure falling from 140/90 to 118/84; his dose and frequency had also changed. Another reported lower blood pressure and easier urination but did not say which cypionate product he had used. [69], [70]
  • Better on cypionate. A man who felt his erections and trough results were worse on enanthate later wondered whether age and changes in exercise and diet explained it. After a shortage moved a UK man onto cypionate, he felt more stable but lost libido and morning erections; he had also lowered his dose before the switch. [71], [72]
  • Blaming the ester for something else. One man blamed cypionate for poor sleep, then slept well again after stopping a bedtime injection of another product, without changing ester. [73]

What about pain, lumps and swelling?

These are the most common complaints after a switch, and several involve non-prescription products, higher strengths or daily subcutaneous injections. One man had painful lumps and felt unwell on a substitute enanthate vial from a different source; another's lumps after switching to cypionate eased when he injected a larger volume less often and deeper. A man who moved between cypionate in grapeseed oil, enanthate in sesame oil and cypionate in MCT oil, changing his dose too, could not tell which change mattered for his acne and lumps. Another, who reacted badly to products listing benzyl benzoate, could not easily get preservative-free Xyosted. [74], [75], [76], [77]

What practical problems come up?

  • Concentration mix-ups. One man switched to a vial of a different strength, kept drawing the same volume and took about 500 mg a week instead of 200 mg for about two weeks; replies pointed to the dose rather than the ester for the changes he felt. During a shortage, another was offered enanthate, apparently with instructions to use half his usual amount, and was unsure what dose that meant. [78], [79]
  • Pharmacy substitutions. One man found at refill that his pharmacy had supplied cypionate instead of the enanthate he had used for 3 months, with no change from his doctor. [80]
  • Cost and supply. A UK man whose pharmacy could not supply enanthate was quoted more than double the price for cypionate. When insurance stopped covering Xyosted, a US man moved to cypionate vials and found the first injection painless. [54], [81]

How can you judge a switch story?

Ask: Were both products prescribed and from a pharmacy? What were the strengths (mg/mL) and the dose in mg, not just mL? Did the schedule, route, needle or oil change too? Was blood drawn at the same point in the interval before and after? What else started or stopped around the same time? These selected discussions show what people experience; they are not a survey of all users or evidence that one ester works better.

Common questions about cypionate vs enanthate

Is testosterone cypionate better than enanthate?

No study shows that either is better. The only direct comparison found identical blood levels at equal testosterone content, and guidelines give them the same doses. The practical choice is usually the product that is available, affordable and tolerated where you live, with the dose set by your prescriber. [3], [8], [10] See what guidelines say.

Is one more painful, or more likely to cause lumps?

No study has compared them. Pain reports after a switch often involve a change of oil, strength, source or route at the same time. If a new product hurts more or leaves lumps, tell your prescriber. [37], [82] See what is in each vial.

Does one cause more estrogen, acne or water retention?

No study has compared the esters on estradiol, acne or fluid retention. Estradiol rises with the testosterone level from either one, so the dose and the size of the peak matter more than the ester. [28], [45] See estrogen on TRT.

Why can't I get cypionate in the UK or Australia?

No cypionate product holds a licence in either country, so prescribers there use licensed enanthate, Sustanon 250 (a mix of four other esters), long-acting undecanoate or gels. UK patients can get cypionate only as an imported unlicensed medicine. [22], [23], [27], [43] See where each is sold.

Is Xyosted enanthate, and is Azmiro cypionate?

Yes. Xyosted is enanthate in a weekly subcutaneous autoinjector for the abdomen, starting at 75 mg. Azmiro is cypionate 200 mg/mL for intramuscular injection, including a prefilled syringe given by a health professional. Depo-Testosterone is cypionate. [2], [17], [1] See the enanthate and cypionate guides.

My pharmacy switched my ester without asking. Is that allowed?

FDA does not rate the two esters as equivalent, so a US pharmacist cannot treat one as a generic version of the other; a change needs the prescriber's approval. Check the strength on the new label before your next dose. [11], [80] See can a pharmacy swap one for the other.

Glossary

Plain explanations of the medical, product and research terms used in this guide. Underlined terms in the text link here.

Ampoule
A sealed glass container holding one dose, opened by snapping the neck. UK and European enanthate comes in 1 mL ampoules of 250 mg.
Autoinjector
A prefilled, single-use device that delivers a fixed dose when pressed against the skin. Xyosted is a weekly testosterone enanthate autoinjector.
Azoospermia
No sperm at all in a semen sample.
Carrier oil (vehicle)
The oil a testosterone ester is dissolved in, such as cottonseed, sesame, castor or peanut oil. It depends on the product and country, not on the ester.
Concentration (strength)
How much medicine is in each milliliter, written as mg/mL. The same dose is a smaller volume at a higher concentration: 100 mg is 0.5 mL at 200 mg/mL and 0.4 mL at 250 mg/mL.
Controlled substance
A medicine whose prescribing and possession are restricted by law because it can be misused. Testosterone is Schedule III in the US, Schedule IV in Canada and Class C in the UK.
Controlled trial
A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.
Crossover study
A study in which each person receives both treatments, one after the other, so each person is compared with themselves.
Depot
A pool of medicine left in the body, such as oil in a muscle, that releases the drug slowly over days or weeks.
Dose (amount each time)
The amount given on one occasion. A protocol lists both the dose and how often it is given.
Ester
A chemical tail joined to testosterone that makes it dissolve in oil and release slowly after injection. The body removes the tail to free testosterone. Cypionate, enanthate and undecanoate are esters.
Estradiol
The main form of estrogen. In men it is made mostly from testosterone, so it rises when testosterone rises.
Half-life
The time it takes for the level of a substance in the blood to fall by half. For testosterone esters, quoted figures mostly reflect slow release from the oil depot, and they vary with how they were measured.
Hazard ratio
A number that compares how often an event happens in one group and another over time. A ratio of 1.0 means the same risk in both groups; below 1.0 means a lower risk and above 1.0 a higher one. TRAVERSE's 0.96 for heart attack, stroke or heart death means about the same risk on testosterone and on placebo.
Hematocrit
The share of the blood made up of red blood cells. Testosterone raises it, and most guidelines act when it reaches about 54%.
Hypogonadism
Low testosterone caused by a problem in the testicles or in the brain and pituitary signals that control them, confirmed with symptoms and repeated morning blood tests.
Intramuscular (IM)
Injected into a muscle. US cypionate and enanthate vials are labeled for deep injection into the buttock muscle.
Meta-analysis
A study that pools the results of many earlier trials. A network meta-analysis also compares treatments that were never tested head to head, by linking trials that share a comparison such as placebo.
Mid-interval level
A blood test taken halfway between two injections, such as day 7 of a 2-week schedule. Several guidelines use it to judge the dose.
Multi-dose vial
A vial meant for several doses, with a preservative. US cypionate comes in 10 mL and US enanthate in 5 mL multi-dose vials.
NADAC
The National Average Drug Acquisition Cost: the average price US pharmacies pay for a medicine, published weekly by the US government. It is not what a patient pays.
Pharmaceutical alternative
FDA's term for products with the same active part but a different salt or ester, such as cypionate and enanthate. They are not rated as interchangeable at the pharmacy.
Pharmacokinetics
How the body absorbs, moves, breaks down and removes a substance.
Placebo
A dummy treatment with no active ingredient, used as a comparison in studies.
Pulmonary oil microembolism (POME)
Tiny droplets of injected oil reaching the lungs, causing a sudden cough or shortness of breath soon after an injection. It is rare with either ester.
Preservative
An ingredient that stops germs from growing in a multi-dose vial, such as benzyl alcohol (US cypionate) or chlorobutanol (US enanthate vials). Xyosted and the single-use enanthate ampoules and syringes sold in the UK, Australia, France, Germany and Sweden list none.
Subcutaneous (SC)
Injected into the fatty layer just under the skin. Xyosted is labeled for it; US vials of both esters are labeled for muscle only, but a UK guideline accepts weekly subcutaneous doses.
Syringe units
Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL, so 0.5 mL is 50 units.
Trough level
The lowest level of a drug in the blood, measured just before the next dose. Some UK guidelines and the Xyosted label judge injections by it.
TRT (testosterone replacement therapy)
Prescribed testosterone, by injection, gel or other forms, for men with low testosterone.
WADA
The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is banned at all times.
Weekly total
All the amounts given in one week, added together. For example, 50 mg twice a week is a 100 mg weekly total, and 200 mg every 2 weeks averages 100 mg a week.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: product labels from the United States, Canada, the United Kingdom, Australia and five European countries, clinical guidelines, FDA and other regulatory records, government price data and published studies. We also reviewed public online forums where men describe switching between the two esters.

The guide cites 82 sources, including 18 product labels and product information documents, 8 clinical guidelines and 16 studies and reports in people, plus 20 public community threads. Each type of source answers a different question. Labels and regulators show what is approved and what is in each product. Guidelines show how clinicians are told to use them. Studies show what was measured. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources

These are the documents cited in this guide. Labels, regulators, guidelines, studies and personal accounts answer different questions. A source being listed does not mean every statement on its page is endorsed.

Showing 82 sources

  1. 01

    DEPO-Testosterone (testosterone cypionate) injection, USP CIII ↗

    Product label (US)

    Full label reviewed.

    Detail: 50–400 mg every 2–4 weeks, deep in the buttock muscle; half-life about 8 days; molecular weight 412.61; each mL of 200 mg/mL holds cottonseed oil, benzyl benzoate and benzyl alcohol 9.45 mg; warming and shaking redissolves crystals; 1 mL and 10 mL vials.

  2. 02

    XYOSTED (testosterone enanthate) injection, for subcutaneous use, CIII ↗

    Product label (US)

    Full label reviewed, including the Instructions for Use.

    Detail: 50, 75 or 100 mg in 0.5 mL sesame oil, no preservative; molecular weight of testosterone enanthate 400.59; starts at 75 mg weekly in the abdomen and is adjusted on a trough level 7 days after a dose; contraindicated with allergy to sesame oil.

  3. 03

    Taro-Testosterone Cypionate Injection 100 mg/mL: Product Monograph (Canada) ↗

    Product monograph (Canada)

    Full label reviewed.

    Detail: 100 mg/mL in cottonseed oil; 200 mg every 2 weeks, at most 400 mg a month; discard 56 days after first use; describes the 1980 crossover of 200 mg cypionate and 194 mg enanthate in 6 healthy men (peak about 1,350 ng/dL at 24 hours, back to about 500 ng/dL by day 10); notes testosterone may be synthesized from soy.

  4. 04

    Testosterone Enanthate Injection USP 200 mg/mL (Hikma Canada): Product Monograph ↗

    Product monograph (Canada)

    Full product monograph reviewed.

    Detail: 200 mg/mL in sesame oil with chlorobutanol, 5 mL vial; usual dose 100–400 mg every 4 weeks; describes the 1980 crossover in which equal testosterone doses of enanthate (194 mg) and cypionate (200 mg) gave identical levels, peaking on days 1–2 and back to baseline by day 10.

  5. 05

    Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate ↗

    Human trial (randomized crossover)

    Title and citation only; no abstract is available and the full text could not be opened. Results in this guide come from the two Health Canada monographs that describe it.

    Result detail: The only direct comparison of the two esters in people: 6 healthy men, one injection of each at equal testosterone content.

  6. 06

    ANDROTARDYL 250 mg/1 ml, solution injectable: résumé des caractéristiques du produit ↗

    Product information (France)

    Full product information reviewed.

    Detail: 250 mg every 2–4 weeks intramuscularly, very slowly; interval judged by the level at its end; release half-life about 4.5 days; use immediately after opening; 65% reimbursed, €6.53 per ampoule (checked September 2026).

  7. 07

    Testosterone enanthate injection, USP CIII (Hikma) ↗

    Product label (US)

    Full label reviewed.

    Detail: 200 mg/mL in sesame oil with chlorobutanol 5 mg/mL, 5 mL multi-dose vial; 50–400 mg every 2–4 weeks, slowly and deeply into the buttock muscle; says doses above 400 mg a month are not required and injections more often than every 2 weeks are rarely indicated; warming and rotating the vial redissolves crystals.

  8. 08

    Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Enanthate or cypionate 75–100 mg weekly or 150–200 mg every 2 weeks; measure midway between injections and adjust above 600 or below 350 ng/dL; stop if hematocrit is above 54%.

  9. 09

    Testosterone Enantate 250 mg/ml solution for injection ampoules: Summary of Product Characteristics ↗

    Product information (UK)

    Full product information reviewed.

    Detail: 250 mg (about 180 mg testosterone) in 1 mL castor oil with benzyl benzoate; 250 mg every 2–3 weeks, then every 3–6 weeks, with the interval set by the level at its end; after 250 mg, peak about 1,233 ng/dL at 24 hours; blood half-life 2–3 days; inject very slowly.

  10. 10

    NADAC (National Average Drug Acquisition Cost) 2026: testosterone cypionate and enanthate ↗

    Government price data (US)

    Structured data reviewed.

    Detail: What pharmacies pay, not what patients pay, per mL: generic cypionate 200 mg/mL in 10 mL vials $3.58 (9 of 10 product codes), 1 mL single-dose vials $11.39, 100 mg/mL $4.53; generic enanthate 200 mg/mL $14.48 (one product code).

  11. 11

    Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book): Preface ↗

    FDA rules on equivalence

    Original page reviewed.

    Detail: Different esters of the same active moiety are different active ingredients (pharmaceutical alternatives), so they are not therapeutically equivalent; injectable oil solutions are equivalent only when the ingredient, concentration and oil are all identical.

  12. 12

    21 CFR 1308.13 Schedule III (anabolic steroids) ↗

    Regulation (US)

    Original page reviewed.

    Detail: Anabolic steroids, including testosterone and its esters, are Schedule III.

  13. 13

    Controlled Drugs and Substances Act (S.C. 1996, c. 19), Schedule IV ↗

    Legislation (Canada)

    Original page reviewed.

    Detail: Anabolic steroids, including testosterone, are Schedule IV.

  14. 14

    Misuse of Drugs Act 1971, Schedule 2 Part III (Class C drugs) ↗

    Legislation (UK)

    Original page reviewed.

    Detail: Testosterone is a Class C controlled drug.

  15. 15

    Therapeutic Goods (Poisons Standard, June 2026) Instrument 2026 ↗

    Legislation (Australia)

    Original page reviewed.

    Detail: Testosterone is Schedule 4 (prescription only), with Appendix D controls on possession.

  16. 16

    World Anti-Doping Code International Standard: Prohibited List 2026 ↗

    Anti-doping rule

    Original document reviewed.

    Detail: Testosterone and its esters are S1 anabolic agents, prohibited at all times.

  17. 17

    AZMIRO (testosterone cypionate) injection, for intramuscular use, CIII ↗

    Product label (US)

    Full label reviewed.

    Detail: 200 mg/mL single-dose vial or prefilled syringe (200 mg doses only, given by a healthcare professional); benzyl alcohol 20 mg/mL; says injectable testosterone products are not substitutable milligram for milligram; carries TRAVERSE results; store at 15–25 °C.

  18. 18

    Testex Prolongatum 100 mg/2 ml y 250 mg/2 ml solución inyectable (cipionato de testosterona): ficha técnica ↗

    Product information (Spain)

    Full product information and register status reviewed.

    Detail: Authorised and marketed in Spain; generally 100–250 mg intramuscular every 2–4 weeks; olive oil and ethyl oleate vehicle.

  19. 19

    Primoteston Depot (testosterone enantate) Australian Product Information ↗

    Product information (Australia)

    Full product information reviewed.

    Detail: 250 mg/mL prefilled syringe in castor oil with benzyl benzoate; every 2–3 weeks, then every 3–4 weeks (up to 6 in many cases); inject extremely slowly; duration of action about 2–4 weeks.

  20. 20

    Testosteron Depot PANPHARMA 250 mg/ml Injektionslösung: Fachinformation ↗

    Product information (Germany)

    Full product information reviewed.

    Detail: 250 mg every 2–3 weeks, then every 3–4 weeks; peak above the normal range at 24 hours; half-life given as 8 days; levels raised for 12–14 days. Current German marketing status not established.

  21. 21

    Testosterone cypionate injection, USP 200 mg/mL (Hikma) ↗

    Product label (US)

    Full label reviewed.

    Detail: Generic cypionate with the same cottonseed oil, benzyl benzoate and benzyl alcohol formula as Depo-Testosterone; 10 mL multi-dose vial.

  22. 22

    Testosterone medicines with current UK product information (electronic medicines compendium) ↗

    Product information listings (UK)

    Current listings reviewed.

    Detail: Current UK testosterone products are gels (Testogel, Irisel, Tostran, Testavan), undecanoate injections (Nebido, Roxadin), Sustanon 250 and Testosterone Enantate; no cypionate product. A listing shows authorisation, not stock.

  23. 23

    Testosterone medicines with current Australian product information (TGA) ↗

    Product information listings (Australia)

    Current product information documents reviewed.

    Detail: Current documents cover undecanoate injections (Reandron, Rejunon, Gonadron), Primoteston Depot (enanthate), Sustanon 250, Testogel, Testavan and AndroForte 5; no cypionate product. Cancellation dates for other products were not verified.

  24. 24

    CIMA: testosterone medicines authorised in Spain ↗

    Regulator database (Spain)

    Structured records reviewed.

    Detail: No testosterone enanthate product is authorised in Spain; injections there are cypionate, propionate and undecanoate.

  25. 25

    Testosterone cypionate injection, USP 200 mg/mL (Padagis) ↗

    Product label (US)

    Full label reviewed.

    Detail: Same formula as Depo-Testosterone; 1 mL and 10 mL vials.

  26. 26

    Testosterone enanthate injection, USP multiple-dose vial (Eugia) ↗

    Product label (US)

    Full label reviewed.

    Detail: Generic 200 mg/mL vial label with the same dosing as the Hikma label.

  27. 27

    Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Enanthate or cypionate 150–200 mg every 2 weeks, or 50–100 mg intramuscular or subcutaneous weekly; adjusts by the trough level aiming for the lower end of normal; says weekly subcutaneous doses have comparable levels, safety and tolerability.

  28. 28

    Hormone kinetics after intramuscular testosterone cypionate ↗

    Human study

    Original abstract reviewed.

    Result detail: In 11 men with hypogonadism, 200 mg tripled testosterone (peak days 2–5) and estradiol (days 2–7); values returned to baseline by days 13–14.

  29. 29

    Treatment of male hypogonadism with testosterone enanthate ↗

    Human study

    Original abstract reviewed.

    Result detail: 100 mg weekly, 200 mg every 2 weeks and 300 mg every 3 weeks kept testosterone mostly normal; 400 mg every 4 weeks did not keep LH suppressed.

  30. 30

    EAU Guidelines on Sexual and Reproductive Health, Chapter 3: Male Hypogonadism ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Cypionate and enanthate are short-term esters given every 2–4 weeks; its injectable table lists half-lives of 8 days for cypionate and 4–5 days for enanthate.

  31. 31

    Testosteronum Prolongatum Jelfa 100 mg/ml roztwór do wstrzykiwań: Charakterystyka Produktu Leczniczego ↗

    Product information (Poland)

    Full product information reviewed.

    Detail: Enanthate 100 mg/mL in peanut (arachis) oil with benzyl alcohol 50 mg/mL; not for people allergic to peanuts or soy; half-life 2 to 3 days; cloudiness or crystals do not mean the product has expired. Current marketing status not verified.

  32. 32

    Testosteronenantat SIT 250 mg/ml solution for injection: Summary of Product Characteristics ↗

    Product information (Sweden)

    Full product information reviewed.

    Detail: 250 mg (about 180 mg testosterone) per 1 mL ampoule in castor oil with benzyl benzoate; apparent half-life 4.2 days after 200 mg intramuscular in men with hypogonadism. National marketing status not established.

  33. 33

    Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study ↗

    Human trial (randomized, with a non-randomized comparison group)

    Original full text reviewed.

    Result detail: Phase II study of a subcutaneous enanthate autoinjector with an intramuscular enanthate comparison group of 10 men on 200 mg every 2 weeks; apparent half-life about 7.2 days intramuscular.

  34. 34

    Population Pharmacokinetic/​Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects ↗

    Human study (modeling)

    Original full text reviewed.

    Result detail: Model of 31 healthy men given 100, 250 or 500 mg of cypionate weekly for 14 weeks in a study of long-term abuse effects; median half-life 4.05 days for total testosterone. Doses are well above replacement doses.

  35. 35

    Anaphylaxis Triggered by Benzyl Benzoate in a Preparation of Depot Testosterone Undecanoate ↗

    Human report (case report)

    Original full text reviewed.

    Result detail: One man had anaphylaxis after testosterone undecanoate injection; skin testing pointed to benzyl benzoate, not castor oil or the hormone.

  36. 36

    Basophil activation test as a helpful tool for the diagnostic and treatment of a case of anaphylaxis due to a castor oil-containing testosterone preparation ↗

    Human report (case report)

    Original abstract reviewed.

    Result detail: One man with anaphylaxis after testosterone undecanoate injection tested strongly positive to castor oil.

  37. 37

    Tolerability of intramuscular injections of testosterone ester in oil vehicle ↗

    Human study

    Original abstract reviewed.

    Result detail: 551 nurse-given weekly enanthate injections in castor oil; minor local effects after 29.4%; brief cough with faintness after 8 (1.5%).

  38. 38

    Medicare Part D Spending by Drug, data year 2024: testosterone cypionate ↗

    Government spending data (US)

    Structured data reviewed.

    Detail: Generic cypionate: 1,118,253 claims for 281,637 people; $37.01 average gross spending per claim before rebates.

  39. 39

    Medicare Part D Spending by Drug, data year 2024: testosterone enanthate and Xyosted ↗

    Government spending data (US)

    Structured data reviewed.

    Detail: Xyosted: 36,669 claims for 6,819 people, $788 gross per claim; generic enanthate: 10,421 claims for 3,734 people, $76 gross per claim (before rebates).

  40. 40

    Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (testosterone cypionate) ↗

    FDA product listing

    Structured data reviewed.

    Detail: Lists Depo-Testosterone 100 and 200 mg/mL, Azmiro (its own reference product, no equivalence code) and AO-rated generics from several makers.

  41. 41

    Orange Book data files: testosterone enanthate products ↗

    FDA product listing

    Structured data reviewed.

    Detail: Marketed: Xyosted (NDA 209863, approved Sep 28, 2018) and 200 mg/mL generic vials from Hikma, Nexus and Eugia (AO-rated). Delatestryl is discontinued, with a determination that it was not withdrawn for safety or effectiveness. No generic Xyosted.

  42. 42

    Drug Product Database: testosterone products and status history ↗

    Regulator database (Canada)

    Structured database records reviewed.

    Detail: Taro cypionate marketed; Depo-Testosterone cancelled July 18, 2025; StériMax cypionate approved July 20, 2026, not marketed; all testosterone products listed under CDSA Schedule IV.

  43. 43

    FOI 23/659: notifications of intent to import unlicensed testosterone and hCG products ↗

    Regulator record (UK)

    Original document reviewed.

    Detail: Since January 2021, six UK licence holders notified the regulator of their intent to import unlicensed testosterone cypionate, and five for enanthate.

  44. 44

    Base de données publique des médicaments: data files for testosterone enanthate products ↗

    Regulator database (France)

    Structured data reviewed.

    Detail: Generic Testosterone Desma 250 mg/1 mL also marketed (authorised Aug 21, 2024; €6.01, 65% reimbursed); neither enanthate product is on the supply-problem list.

  45. 45

    Evaluation and Management of Testosterone Deficiency: AUA Guideline ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Prefers smaller, more frequent doses of short-acting injections (100 mg weekly over 200 mg every 2 weeks or 300–400 mg monthly); on cypionate or enanthate, first check testosterone no earlier than after 3–4 injections; measures estradiol mainly with breast symptoms; no testosterone for men trying to conceive.

  46. 46

    Evaluation for and Management of Males with Low Testosterone: Recommendations for Use ↗

    Health-system clinical recommendations

    Original full text reviewed.

    Detail: Cypionate or enanthate typically every 2–4 weeks; 50–100 mg weekly or 100–200 mg every 2 weeks; flags either ester above 100 mg a week as a possible sign of misuse.

  47. 47

    Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Lists Canadian products separately: enanthate 100–200 mg every 1–4 weeks; cypionate 200 mg every 2 weeks or 100 mg weekly; mid-cycle monitoring.

  48. 48

    The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Lists enanthate every 2–3 weeks and cypionate every 1–4 weeks, with little long-term published data for cypionate; says UK choices of licensed products usually lie between gels and long-acting undecanoate.

  49. 49

    Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; amended 2024) ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Clinicians should not prescribe testosterone to men interested in current or future fertility.

  50. 50

    Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients ↗

    Human study

    Original abstract reviewed.

    Result detail: 63 transgender men on weekly subcutaneous cypionate or enanthate reached the male range; all 22 who switched preferred subcutaneous injection.

  51. 51

    Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate ↗

    Human study (observational)

    Original abstract reviewed.

    Result detail: 234 men; the subcutaneous enanthate autoinjector group had lower hematocrit and estradiol; route, ester and device all differed.

  52. 52

    Mixing - Cypionate & Enanthate ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Asked about storing leftover enanthate from an ampoule in an emptied cypionate vial; replies raised contamination concerns.

  53. 53

    FDA Drug Shortages data (openFDA) ↗

    Regulator database (US)

    Structured data reviewed.

    Detail: No current, resolved or discontinued shortage record for any testosterone product.

  54. 54

    Testosterone Enanthate Shortage ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: UK pharmacy could not supply enanthate and quoted cypionate at more than double the earlier price.

  55. 55

    Enanthate shortage / discontinuation? ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Long-term enanthate user who reported flu-like reactions on cypionate; local pharmacies described enanthate as backordered while others still filled it.

  56. 56

    Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen ↗

    Human study (observational)

    Original full text reviewed.

    Result detail: The 57 men on injections used 100–200 mg of cypionate or enanthate weekly and were analyzed as one group, so the study cannot compare the two esters.

  57. 57

    The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials ↗

    Meta-analysis of trials

    Original abstract reviewed.

    Result detail: 29 trials; hematocrit rise vs placebo about 4.0 points for enanthate or cypionate injections, 3.0 for gel, 1.6 for undecanoate injections. Only injections vs patch differed significantly; injections vs gel did not.

  58. 58

    Contraceptive efficacy of testosterone-induced azoospermia in normal men ↗

    Human trial

    Original abstract reviewed.

    Result detail: 271 healthy men on 200 mg enanthate weekly; 157 became azoospermic in three consecutive samples (cumulative rate at 6 months 65%).

  59. 59

    Testosterone suppression of the HPT axis ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: Cypionate 100 mg a week made LH and FSH undetectable within 5–6 weeks and impaired sperm production; effects reversed after stopping.

  60. 60

    AVEED (NDA 022219) cross-discipline team leader review ↗

    FDA review

    Original document reviewed.

    Detail: Rare reports of severe oil microembolism and anaphylaxis with enanthate and cypionate; 33 reports over 44 years across all approved testosterone injections combined.

  61. 61

    Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE) ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: 5,204 men on daily gel or placebo; heart attack, stroke or heart death 7.0% vs 7.3% (hazard ratio 0.96); mean treatment 21.7 months.

  62. 62

    Testosterone Treatment and Fractures in Men with Hypogonadism ↗

    Human trial (randomized; TRAVERSE substudy)

    Original abstract reviewed.

    Result detail: Clinical fractures 91 of 2,601 (3.50%) vs 64 of 2,603 (2.46%).

  63. 63

    FDA issues class-wide labeling changes for testosterone products ↗

    Regulator notice (US)

    Original page reviewed.

    Detail: Adds TRAVERSE results and blood-pressure warnings to testosterone labels, removes boxed-warning language on heart risk and recounts the 2015 age-related limitation.

  64. 64

    HHS Announces Requested Updates to Testosterone Therapy Product Labels ↗

    Regulator notice (US)

    Original page reviewed.

    Detail: FDA is requesting removal of the age-related limitation, a contraindication only in metastatic prostate cancer, and a revised prostate-enlargement warning; requested, not yet in labels (checked September 2026).

  65. 65

    World Anti-Doping Code International Standard: Prohibited List 2027 ↗

    Anti-doping rule

    Original document reviewed.

    Detail: Keeps testosterone prohibited at all times.

  66. 66

    If you could choose, would you take Enanthate, Sustanon or Cyprionate as TRT? ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: A commenter switched by the pharmacy from cypionate to enanthate noticed no difference over 12 weeks.

  67. 67

    Test E vs Cyp for everyday microdosing ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Discussion of daily injections; a commenter who used both at the same weekly dose reported no change and stable blood results.

  68. 68

    Anyone have to switch between enanthate and cypionate? (enanthate shortage) ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Clinic ran out of enanthate; most replies reported no change after switching, some reported differences in libido, pain or reactions.

  69. 69

    Test C to Test E ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: After several cypionate schedules, moved to enanthate 75 mg weekly; reported steadier weeks, better libido and blood pressure falling from 140/90 to 118/84 on the same blood pressure medicine. Dose and frequency had also changed.

  70. 70

    Switched from Cypionate to Enanthate — Blood Pressure Down, Prostate Back to Normal ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Reported lower blood pressure and easier urination after moving to a sesame-oil enanthate; the cypionate product's oil was not identified.

  71. 71

    Enathate vs Cypionate experience (I saw differences) ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Felt erections were worse and trough results less favorable on enanthate; later raised age, exercise and diet changes as possible explanations.

  72. 72

    Swapkng from test e to testc ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Shortage-driven switch from enanthate to cypionate; felt more stable but lost libido and morning erections after a month; the enanthate dose had been lowered shortly before.

  73. 73

    Improved sleep on Test E vs Test C? ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Blamed cypionate for poor sleep, then found sleep recovered after stopping a bedtime peptide injection, without changing ester.

  74. 74

    Injection Site Lumps ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Painful lumps and feeling unwell on a substitute enanthate vial from a different source; planned to return to cypionate.

  75. 75

    I switched from Test E to C and get hard lumps ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Hard lumps after switching to cypionate on daily 0.12 mL subcutaneous injections; improved with 0.22 mL every other day, injected deeper.

  76. 76

    Enanthate online provider? ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Acne and injection lumps changed as he moved between cypionate in grapeseed oil, enanthate in sesame oil and cypionate in MCT oil, with a dose change as well.

  77. 77

    Sensitive to preservatives in regular T, should I move to Xyosted? ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Severe local reactions to products that listed benzyl benzoate; considered preservative-free Xyosted, which was hard to obtain where he lived.

  78. 78

    Accidental High Dose Experience that felt amazing, DHT vs Total Testosterone Effects? ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Kept the same injection volume after switching to a vial of a different strength and took about 500 mg a week instead of 200 mg for about two weeks. Commenters attributed the changes he noticed to the dose, not the ester.

  79. 79

    Pharmacy wants to switch up Test ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: During a shortage, enanthate was offered with instructions to use half the usual amount, leaving him unsure of the dose.

  80. 80

    Probably a stupid Question ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Pharmacy supplied cypionate at refill instead of the enanthate he had used for 3 months, with no change from his doctor.

  81. 81

    Switching from SubQ to IM — expectations? ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Lost insurance cover for Xyosted and moved to intramuscular cypionate; mild soreness the next day; the autoinjector had helped with needle fear.

  82. 82

    Lumps Test C / Test E ↗

    Community account

    Public thread and comments reviewed; no usernames used.

    Account: Persistent lumps after subcutaneous injections of both esters, despite changing needles and injecting slowly.

Updates and corrections

Updated September 29, 2026. This is a new guide, first published September 28, 2026. It replaces the cypionate-versus-enanthate answers scattered across the earlier testosterone injection, cypionate, enanthate and Xyosted pages, and corrects several of them: the two esters were never shown to be clinically interchangeable in a trial, only to give identical levels in one small single-dose study; the 2,261 ng/dL enanthate peak quoted as a comparison came from an enanthate-only group in a different study; 100 mg of either ester contains about 70–72 mg of testosterone, not 88–89 mg; there is no single enanthate half-life; Sustanon 250 is a mix of four other esters, not enanthate; Azmiro is labeled for intramuscular use only; and no study shows that preservative-free Xyosted is better tolerated. The date describes this revision, not a fresh check of every source.

Found an error or a relevant study we missed? Report a correction with the guide title, the specific passage and a supporting source if available. Please leave out personal health records. See our editorial policy for how we handle attribution, evidence limits and corrections.